Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs

Molecular Pharmacology

Volumn 72, Issue 2, 2007, Pages 311-319

  Lansiaux, Amélie ^a,d   Léonce, Stéphane ^b   Kraus Berthier, Laurence ^b   Bal Mahieu, Christine ^a   Mazinghien, Romain ^a   Didier, Sébastien ^a   David Cordonnier, Marie Hélène ^a   Hautefaye, Patrick ^b   Lavielle, Gilbert ^b   Bailly, Christian ^a,c   Hickman, John A ^b   Pierré, Alain ^b  

^a INSERM   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^d JEAN PIERRE AUBERT RESEARCH CENTER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DIFLOMOTECAN; DNA TOPOISOMERASE INHIBITOR; HISTONE H2AX; IRINOTECAN; LACTONE; S 36272; S 38769; S 38809; TOPOTECAN; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CELL CULTURE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA STRAND BREAKAGE; DRUG PROTEIN BINDING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STEREOCHEMISTRY; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CASPASES; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; DIOXOLES; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; G2 PHASE; HUMANS; PHOSPHORYLATION;

EID: 34547182993     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.034637     Document Type: Article

References (40)

1. Bailly C (2000) Topoisomerase I poisons and suppressors as anticancer drugs. Current Med Chem 7:39-58.
2. Bailly C (2001) DNA relaxation and cleavage assays to study topoisomerase I inhibitors. Methods Enzymol 340:610-623.
3. Bailly C (2003) Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit Rev Oncol Hematol 45:91-108.
4. Bailly C, Lansiaux A, Dassonneville L, Demarquay D, Coulomb H, Huchet M, Lavergne O, and Bigg DC (1999) Homocamptothecin, an E-ring modified camptothecin analog, generates new topoisomerase I-mediated DNA breaks. Biochemistry 38:15556-15563.
5. Banáth JP and Olive PL (2003) Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 63:4347-4350.
6. Bonneterre J, Cottu P, Adenis A, Bonneterre ME, Obach R, Principe P, Seguy F, Wright S, and Marty M (2000) Phase I trial of BN80915 administered intravenously in patients with advanced malignant tumors (Abstract). Proc Am Assoc Cancer Res 41:234a.
7. Boyd MR and Paull KD (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res 34:91-109.
8. Burke TG and Bom D (2000) Camptothecin design and delivery approaches for elevating anti-topoisomerase I activities in vivo. Ann N Y Acad Sci 922:36-45.
9. Burke TG and Mi Z (1993) Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J Med Chem 36:2580-2582.
10. Burke TG and Mi Z (1993) Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 212:285-287.
11. Fan Y, Weinstein JN, Kohn KW, Shii LM, and Pommier Y (1998) Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. J Med Chem 41:2216-2226.
12. Fournet-Bourguignon MP, Castedo-Delrieu M, Bidouard JP, Leonce S, Saboureau D, Delescluse I, Vilaine JP, and Vanhoutte PM (2000) Phenotypic and functional changes in regenerated porcine coronary endothelial cells: increased uptake of modified LDL and reduced production of NO. Circ Res 86:854-861.
13. Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, Sedelnikova OA, Pilch DR, Rogakou EP, Celeste A, Chen HT, et al. (2003) Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 278:20303-20312.
14. Hautefaye P, Cimetière B, Pierré A, Leonce S, Hickman J, Laine W, Bailly C, and Lavielle G (2003) Synthesis and pharmacological evaluation of novel E-ring nonlactone analogues of camptothecin. Bioorg Med Chem Lett 13:2731-2735.
15. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK, and Kingsbury WD (1989) Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32:715-720.
16. Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK, and Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393-403.
17. Hsiang YH, Hertzberg R, Hecht S, and Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878.
18. Hsiang YH, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, Kirschenbaum S, Silber R, and Potmesil M (1989) DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49:4385-4389.
19. Jaxel C, Capranico G, Kerrigan D, Kohn KW, and Pommier Y (1991) Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 266:20418-20423.
20. Kerrigan JE and Pilch DS (2001) A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA and camptothecin. Biochemistry 40:9792-9798.
21. Lansiaux A and Bailly C (2003) A symphony for the camptothecins. Bull Cancer 90:239-245.
22. Lavergne O, Lesueur-Ginot L, Pla Rodas F, Kasprzyk PG, Pommier J, Demarquay D, Prevost G, Ulibarri G, Rolland A, Schiano-Liberatore AM, et al. (1998) Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J Med Chem 41:5410-5419.
23. Léonce S, Kraus-Berthier L, Golsteyn RM, David-Cordonnier MH, Tardy C, Lansiaux A, Poindessous V, Larsen AK, and Pierre A (2006) Generation of replication-dependent double-strand breaks by the novel N2-G-alkylator S23906-1. Cancer Res 66:7203-7210.
24. Léonce S, Perez V, Casabianca-Pignède MR, Anstett M, Bisagni E, Pierre A, and Atassi G (1996) In vitro cytotoxicity of S16020-2, a new olivacine derivative. Invest New Drugs 14:169-180.
25. Léonce S, Pérez V, Lambel S, Peyroulan D, Tillequin F, Michel S, Koch M, Pfeiffer B, Atassi G, Hickman JA, et al. (2001) Induction of cyclin E and inhibition of DNA synthesis by the novel acronycine derivative S23906-1 precede the irreversible arrest of tumor cells in S phase leading to apoptosis. Mol Pharmacol 60:1383-1391.
26. Madelaine I, Prost S, Naudin A, Riou G, Lavelle F, and Riou JF (1993) Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem Pharmacol 45:339-348.
27. Osheroff N (2004) Diflomotecan. Ipsen. IDrugs 7:257-263.
28. Pilch B, Allemand E, Facompré M, Bailly C, Riou JF, Soret J, and Tazi J (2001) Specific inhibition of serine-and arginine-rich splicing factors phosphorylation, spliceosome assembly and splicing by the anti-tumor drug NB-506. Cancer Res 61:6876-6884.
29. Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6:789-802.
30. Pommier Y and Cherfils J (2005) Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends Pharmacol Sci 26:138-145.
31. Pommier Y, Kohlhagen G, Kohn KW, Leteurtre F, Wani MC, and Wall ME (1995) Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc Natl Acad Sci U S A 92:8861-8865.
32. Pourquier P and Pommier Y (2001) Topoisomerase I-mediated DNA damage. Adv Cancer Res 80:189-216.
33. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, and Hol WG (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279:1504-1513.
34. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, and Bonner WM (1998) DNA double-strand breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:5858-5868.
35. Scott L, Soepenberg O, Verweij J, de Jonge M, Th Planting A, McGovern D, Principe P, Obach R, and Twelves C (2002) A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. Ann Oncol 18:569-575.
36. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr, and Stewart L (2002) The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A 99:15387-15392.
37. Strumberg D, Pilon AA, Smith M, Hickey R, Malkas L, and Pommier Y (2000) Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol 20:3977-3987.
38. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, and Sim GA (1966) Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888-3890.
39. Wall ME, Wani MC, Nicholas AW, Manikumar G, Tele C, Moore L, Truesdale A, Leitner P, and Besterman JM (1993) Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J Med Chem 36:2689-2700.
40. Wang X, Zhou X, and Hecht SM (1999) Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex. Biochemistry 38:4374-4381.